An increasing number of studies has revealed several neoantigens that may be used for CAR-T therapies for KRAS-driven cancers, including mesothelin (MSLN), carcinoembryonic antigen (CEA), HER2, MUC1, prostate stem cell antigen (PSCA), NK, and CD24 (95). Here, CEACAM5 is linked to cancer.